(Reuters) - French drugmaker Sanofi-Aventis SA sells the medicine in 18 countries under the name Acomplia. Advisers to the Food and Drug Administration said there were too many questions about potential side effects to support U.S. approval.
"I think this is a drug that needs further understanding with respect to what it does to people's psyche," said Dr. Sid Gilman, a panel member and a University of Michigan neurologist.
Read more at Reuters.com Hot Stocks News
"I think this is a drug that needs further understanding with respect to what it does to people's psyche," said Dr. Sid Gilman, a panel member and a University of Michigan neurologist.
Read more at Reuters.com Hot Stocks News
No comments:
Post a Comment